[Blood pressure lowering and risk reduction under treatment with valsartan and its combination with hydrochlorothiazide (HCT)].
Scholze
J
J
Charité Centrum für Innere Medizin und Dermatologie, Campus Mitte, Medizinische Poliklinik, Luisenstr. 11-13 D-ll117, Berlin.
Müller
U
U
D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D004338:Drug Combinations; D006801:Humans; D006852:Hydrochlorothiazide / Q000009:adverse effects / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy*; D011446:Prospective Studies; D012307:Risk Factors; D013777:Tetrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D014633:Valine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068756:Valsartan
D000959:Antihypertensive Agents; D004338:Drug Combinations; D013777:Tetrazoles; D006852:Hydrochlorothiazide; D000068756:Valsartan; D014633:Valine